MVM Life Science Partners is a leading Venture Capital firm that invests in technologies and products for the life science and healthcare markets. MVM has teams in London and Boston.
2nd February 2010
Vantia Therapeutics' Lead Candidate VA106483 enters Phase IIb Trial for Nocturia
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia
Read this article
2nd February 2010
Galapagos acquires Argenta Discovery’s service operations
Galapagos NV announces the acquisition of Argenta Discovery 2009 Ltd. The combination with Galapagos’ service division BioFocus creates one of the world’s largest drug discovery service organisations
Read this article
Vantia Therapeutics' Lead Candidate VA106483 enters Phase IIb Trial for Nocturia
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia
Read this article
2nd February 2010
Galapagos acquires Argenta Discovery’s service operations
Galapagos NV announces the acquisition of Argenta Discovery 2009 Ltd. The combination with Galapagos’ service division BioFocus creates one of the world’s largest drug discovery service organisations
Read this article
